Miriditas is building a platform technology around MIR100, an innovative drug developed to interrupt inflammation at its source. MIR100 targets the initial immune response that leads to the activation of reactive oxygen species (ROS). MIR100 reduces ROS-related damage in retinal tissue and addresses the underlying pathogenesis of age-related macular degeneration (AMD).